Curis, Inc.
CRIS
Positions held
Your positionsCRIS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $1.72M | Enterprise value | -$2.55M | Trailing P/E | 0.54 | Forward P/E | -0.12 |
| PEG | — | Price / book | 0.29 | Beta | 3.10 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -8.3% |
| Profit margin | 0.0% | ROE | — | ROA | -93.2% | Debt / equity | 0.22 |
| Current ratio | 0.49 | Free cash flow | -$15.77M | Analyst recommendation | none | Mean target | $42.67 |
| 52w high | $33.60 | 52w low | $0.61 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $1.1M | $3.2M | $2.7M | — |
| Op margin | — | — | -665.2% | -218.0% | -300.1% | — |
| Net income | -$8.6M | -$24.2M | $19.4M | -$7.7M | -$8.6M | — |
| Gross margin | — | — | 100.0% | 99.5% | 99.4% | — |
| Gross profit | $0.0M | $0.0M | $1.1M | $3.2M | $2.7M | — |
| Operating income | -$9.9M | -$11.5M | -$7.6M | -$6.9M | -$8.3M | — |
- Gross margin 100% (was 99.5% prior quarter).
- Operating margin compressed to -665.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.4M | $10.9M | $10.0M | $10.2M | — |
| Op margin | -348.4% | -408.3% | -482.2% | -521.7% | — |
| Net income | -$7.6M | -$43.4M | -$47.4M | -$56.7M | — |
| Gross margin | 99.5% | 99.1% | 97.9% | 97.5% | — |
| Gross profit | $9.4M | $10.8M | $9.8M | $9.9M | — |
| Operating income | -$32.9M | -$44.5M | -$48.3M | -$53.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-14 · Curis: Q2 Earnings Snapshot
2026-08-13 · Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors
2026-08-13 · Curis, Inc. Announces Pricing of $5.6 Million Public Offering
2026-08-05 · Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework
2026-07-30 · Curis Doses First Five Patients in TakeAim CLL Study
2026-07-27 · Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
2026-07-22 · Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus
2026-07-22 · Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)
2026-07-22 · Curis Announces Positive Emavusertib Update
Price (daily)
Full chart · RSI · MACD · patterns